Axonics Modulation Technologies (NASDAQ:AXNX) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Axonics Modulation Technologies and Cantel Medical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axonics Modulation Technologies $710,000.00 744.62 -$32.48 million ($4.64) -4.09
Cantel Medical $871.92 million 3.09 $91.04 million $2.51 25.73

Cantel Medical has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Dividends

Cantel Medical pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Axonics Modulation Technologies does not pay a dividend. Cantel Medical pays out 8.0% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Axonics Modulation Technologies and Cantel Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axonics Modulation Technologies 0 0 4 0 3.00
Cantel Medical 0 1 1 0 2.50

Axonics Modulation Technologies currently has a consensus price target of $21.48, suggesting a potential upside of 13.11%. Cantel Medical has a consensus price target of $114.00, suggesting a potential upside of 76.53%. Given Cantel Medical’s higher probable upside, analysts clearly believe Cantel Medical is more favorable than Axonics Modulation Technologies.

Institutional & Insider Ownership

31.9% of Axonics Modulation Technologies shares are held by institutional investors. Comparatively, 86.8% of Cantel Medical shares are held by institutional investors. 11.7% of Cantel Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Axonics Modulation Technologies and Cantel Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axonics Modulation Technologies N/A N/A N/A
Cantel Medical 8.22% 16.18% 10.29%

Summary

Cantel Medical beats Axonics Modulation Technologies on 10 of the 14 factors compared between the two stocks.

About Axonics Modulation Technologies

Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.

About Cantel Medical

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Endoscopy segment offers automated endoscope reprocessing systems; infectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets, transport systems, and mobile medical carts; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Water Purification and Filtration segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratory and pharmaceutical, food and beverage, and commercial industrial customers. The company's Healthcare Disposables segment offers biological indicators, chemical integrators, sterilization pouches, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, amalgam separators, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.